200 related articles for article (PubMed ID: 32618256)
41. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
Matter L; Germann D; Bally F; Schopfer K
Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
[TBL] [Abstract][Full Text] [Related]
42. Low seroprevalence of diphtheria, tetanus and pertussis in ambulatory adult patients: the need for lifelong vaccination.
Tanriover MD; Soyler C; Ascioglu S; Cankurtaran M; Unal S
Eur J Intern Med; 2014 Jul; 25(6):528-32. PubMed ID: 24814432
[TBL] [Abstract][Full Text] [Related]
43. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
[TBL] [Abstract][Full Text] [Related]
44. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
45. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
[TBL] [Abstract][Full Text] [Related]
46. Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients.
Sticchi L; Bruzzone B; Caligiuri P; Rappazzo E; Lo Casto M; De Hoffer L; Gustinetti G; Viscoli C; Di Biagio A
Hum Vaccin Immunother; 2015; 11(1):263-9. PubMed ID: 25483544
[TBL] [Abstract][Full Text] [Related]
47. Uptake of measles containing vaccines in the measles, mumps, and rubella second dose catch-up programme in Wales.
Thomas DR; King J; Evans MR; Salmon RL
Commun Dis Public Health; 1998 Mar; 1(1):44-7. PubMed ID: 9718839
[TBL] [Abstract][Full Text] [Related]
48. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
Heath TC; Burgess MA; O'Brien ED
Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
[No Abstract] [Full Text] [Related]
49. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
50. Seroprevalence of measles, mumps & rubella antibodies among 5-10 years old children in north India.
Gupta M; Tripathy JP; Verma M; Singh MP; Kaur R; Ratho RK; Kumar R
Indian J Med Res; 2019 Mar; 149(3):396-403. PubMed ID: 31249206
[TBL] [Abstract][Full Text] [Related]
51. Potential impact on vaccination coverage levels by administering vaccines simultaneously and reducing dropout rates.
Dietz VJ; Stevenson J; Zell ER; Cochi S; Hadler S; Eddins D
Arch Pediatr Adolesc Med; 1994 Sep; 148(9):943-9. PubMed ID: 8075738
[TBL] [Abstract][Full Text] [Related]
52. Status report on the Childhood Immunization Initiative: reported cases of selected vaccine-preventable diseases--United States, 1996.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Jul; 46(29):665-71. PubMed ID: 9237476
[TBL] [Abstract][Full Text] [Related]
53. Antibody waning after immunosuppressive chemotherapy and immunomodulators, re-immunization considerations in pediatric patients with malignancy and chronic immune thrombocytopenic purpura.
Abdolkarimi B; Amanati A; Molavi Vardanjani H; Jamshidi S; Tabaeian SAP
BMC Infect Dis; 2022 Jul; 22(1):657. PubMed ID: 35902837
[TBL] [Abstract][Full Text] [Related]
54. Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines.
Deforest A; Long SS; Lischner HW; Girone JA; Clark JL; Srinivasan R; Maguire TG; Diamond SA; Schiller RP; Rothstein EP
Pediatrics; 1988 Feb; 81(2):237-46. PubMed ID: 3340474
[TBL] [Abstract][Full Text] [Related]
55. Seroprevalence of vaccine-preventable diseases among children and adolescents in Singapore: Results from the National Paediatric Seroprevalence Survey 2018.
Ng Y; Chua LAV; Cui L; Ang LW; Tee NWS; Lin RTP; Ma S; Lee VJM
Int J Infect Dis; 2020 Mar; 92():234-240. PubMed ID: 31843668
[TBL] [Abstract][Full Text] [Related]
56. Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines.
Rothstein EP; Bernstein HH; Glode MP; Laussucq S; Nonenmacher J; Long SS; Hackell JG
Am J Dis Child; 1993 Aug; 147(8):854-7. PubMed ID: 8394646
[TBL] [Abstract][Full Text] [Related]
57. Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme.
Tharmaphornpilas P; Yoocharean P; Rasdjarmrearnsook AO; Theamboonlers A; Poovorawan Y
J Health Popul Nutr; 2009 Feb; 27(1):80-6. PubMed ID: 19248651
[TBL] [Abstract][Full Text] [Related]
58. The control of diphtheria, tetanus, poliomyelitis, measles, rubella and mumps.
Dudgeon JA
Practitioner; 1975 Sep; 215(1287):299-309. PubMed ID: 1101251
[No Abstract] [Full Text] [Related]
59. Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines.
Paulke-Korinek M; Fischmeister G; Grac A; Rendi-Wagner P; Kundi M; Mohsenzadeh-Rabbani A; Moritz K; Fenninger B; Jarisch R; Jasinska J; Holzmann H; Wiedermann U; Kollaritsch H
Vaccine; 2011 Jul; 29(32):5130-6. PubMed ID: 21624412
[TBL] [Abstract][Full Text] [Related]
60. IgG antibody prevalence suggests high immunization needs in newcomers to Luxembourg, 2012.
Hübschen JM; Charpentier E; Weicherding P; Muller CP
Vaccine; 2018 Feb; 36(6):899-905. PubMed ID: 29306505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
